Equities

Amedisys Inc

Amedisys Inc

Actions
Health CareHealth Care Providers
  • Price (USD)97.21
  • Today's Change0.06 / 0.06%
  • Shares traded381.17k
  • 1 Year change+3.45%
  • Beta0.7811
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold10
Sell1
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Amedisys Inc have a median target of 101.00, with a high estimate of 101.00 and a low estimate of 73.00. The median estimate represents a 3.90% increase from the last price of 97.21.
High3.9%101.00
Med3.9%101.00
Low-24.9%73.00

Earnings history & estimates in USD

On Jul 24, 2024, Amedisys Inc reported 2nd quarter 2024 earnings of 1.32 per share. This result exceeded the 1.19 consensus of the 8 analysts covering the company and under-performed last year's 2nd quarter results by 3.65%.
The next earnings announcement is expected on Oct 22, 2024.
Average growth rate+1.30%
Amedisys Inc reported annual 2023 earnings of 4.30 per share on Feb 21, 2024.
Average growth rate+1.57%
More ▼

Revenue history & estimates in USD

Amedisys, Inc. had 2nd quarter 2024 revenues of 591.19m. This bettered the 578.83m consensus of the 8 analysts covering the company. This was 6.25% above the prior year's 2nd quarter results.
Average growth rate+1.69%
Amedisys, Inc. had revenues for the full year 2023 of 2.24bn. This was 0.17% above the prior year's results.
Average growth rate+3.37%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.